Rilonacept（Cat No.:I042335）is a biologic drug that functions as a recombinant fusion protein, designed to inhibit interleukin-1 (IL-1) activity. It works by binding to IL-1 receptors, preventing the interaction of IL-1 with its receptors and blocking downstream inflammatory signaling. Rilonacept is primarily used to treat autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). By reducing the overactive inflammatory response, rilonacept helps manage symptoms like fever, rashes, and joint pain, improving quality of life for patients with these conditions.
